Received Mar 2, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | FX753 | — |
Exposure in the eye; Inadvertent exposure to vaccine; This non-serious case was reported by other health professional via call center representative and described the occurrence of occupational exposure to product via eye in a female patient who received Herpes zoster (Shingrix) (batch number FX753, expiry date 07-JUL-2027) for prophylaxis. On 20-FEB-2026, the patient received Shingrix. On 20-FEB-2026, an unknown time after receiving Shingrix, the patient experienced occupational exposure to product via eye (Verbatim: Exposure in the eye) and inadvertent exposure to vaccine (Verbatim: Inadvertent exposure to vaccine). The outcome of the occupational exposure to product via eye and inadvertent exposure to vaccine were not applicable. Additional Information: GSK Receipt Date: 20-FEB-2026 Pharmacy intern called on 20-FEB-2026 to report that one of the technicians at the pharmacy accidentally got the Zoster vaccine in her eye, 20-FEB-2026, while they were mixing it. The pharmacy intern stated that it was the liquid that got into the technician's eye, but she did not know whether it occurred before or after the vaccine was reconstituted.